Fate Therapeutics (F6T) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

F6T Analyst Ratings

Moderate Buy

5 Buy

4 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Fate

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

F6T Stock 12 Month Forecast

Average Price Target

€4.55

▲(112.49% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Fate Therapeutics in the last 3 months. The average price target is €4.55 with a high forecast of €6.94 and a low forecast of €1.91. The average price target represents a 112.49% change from the last price of €2.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","3":"€3","5":"€5","7":"€7","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.9387164,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.547337355000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.90814701,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.232,2.594055107692308,2.9561102153846157,3.318165323076923,3.6802204307692308,4.0422755384615385,4.404330646153846,4.766385753846153,5.128440861538461,5.4904959692307695,5.852551076923077,6.214606184615384,6.5766612923076915,{"y":6.9387164,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.232,2.410102873461539,2.588205746923077,2.7663086203846157,2.9444114938461543,3.1225143673076925,3.300617240769231,3.4787201142307698,3.6568229876923084,3.8349258611538466,4.013028734615386,4.191131608076923,4.369234481538462,{"y":4.547337355000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.232,2.207088231538462,2.182176463076923,2.157264694615385,2.132352926153846,2.1074411576923078,2.0825293892307695,2.0576176207692307,2.0327058523076924,2.007794083846154,1.9828823153846153,1.957970546923077,1.9330587784615385,{"y":1.90814701,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.927,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.895,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.032,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.158,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.933,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.817,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.937,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.178,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.019,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.232,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€6.94

Average Price Target€4.55

Lowest Price Target€1.91

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gil Blum

Needham

―

Hold

―

Reiterated

07/10/26

Fate Therapeutics (FATE) Gets a Hold from Needham

Robert Burns

H.C. Wainwright

€6.07

Buy

183.71%

Upside

Reiterated

07/09/26

Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

€6.94

Buy

224.24%

Upside

Reiterated

06/22/26

Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities

Edward Tenthoff

Piper Sandler

€5.2

Buy

143.18%

Upside

Reiterated

06/09/26

Piper Sandler Remains a Buy on Fate Therapeutics (FATE)

Tazeen Ahmad

Bank of America Securities

€1.73→€1.91

Hold

-10.83%

Downside

Reiterated

05/21/26

Bank of America Securities Keeps Their Hold Rating on Fate Therapeutics (FATE)

Roger Song

Jefferies

€3.47

Buy

62.12%

Upside

Initiated

05/19/26

Fate Therapeutics assumed with a Buy at JefferiesFate Therapeutics assumed with a Buy at Jefferies

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

€2.17

Hold

1.32%

Upside

Reiterated

05/14/26

Wells Fargo Remains a Hold on Fate Therapeutics (FATE)

Martin Fan

Wedbush

€6.07

Buy

183.71%

Upside

Reiterated

05/14/26

Wedbush Reaffirms Their Buy Rating on Fate Therapeutics (FATE)

Tara Bancroft

TD Cowen

―

Hold

―

Reiterated

05/13/26

Tara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution Risks

Peter Lawson

Barclays

€1.73

Buy

-18.94%

Downside

Reiterated

10/28/25

Barclays Sticks to Their Buy Rating for Fate Therapeutics (FATE)

Daina Graybosch

Leerink Partners

€10.41→€6.07

Buy

183.71%

Upside

Reiterated

09/04/25

Leerink Partners Sticks to Its Buy Rating for Fate Therapeutics (FATE)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gil Blum

Needham

―

Hold

―

Reiterated

07/10/26

Fate Therapeutics (FATE) Gets a Hold from Needham

Robert Burns

H.C. Wainwright

€6.07

Buy

183.71%

Upside

Reiterated

07/09/26

Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

€6.94

Buy

224.24%

Upside

Reiterated

06/22/26

Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities

Edward Tenthoff

Piper Sandler

€5.2

Buy

143.18%

Upside

Reiterated

06/09/26

Piper Sandler Remains a Buy on Fate Therapeutics (FATE)

Tazeen Ahmad

Bank of America Securities

€1.73→€1.91

Hold

-10.83%

Downside

Reiterated

05/21/26

Bank of America Securities Keeps Their Hold Rating on Fate Therapeutics (FATE)

Roger Song

Jefferies

€3.47

Buy

62.12%

Upside

Initiated

05/19/26

Fate Therapeutics assumed with a Buy at JefferiesFate Therapeutics assumed with a Buy at Jefferies

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

€2.17

Hold

1.32%

Upside

Reiterated

05/14/26

Wells Fargo Remains a Hold on Fate Therapeutics (FATE)

Martin Fan

Wedbush

€6.07

Buy

183.71%

Upside

Reiterated

05/14/26

Wedbush Reaffirms Their Buy Rating on Fate Therapeutics (FATE)

Tara Bancroft

TD Cowen

―

Hold

―

Reiterated

05/13/26

Tara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution Risks

Peter Lawson

Barclays

€1.73

Buy

-18.94%

Downside

Reiterated

10/28/25

Barclays Sticks to Their Buy Rating for Fate Therapeutics (FATE)

Daina Graybosch

Leerink Partners

€10.41→€6.07

Buy

183.71%

Upside

Reiterated

09/04/25

Leerink Partners Sticks to Its Buy Rating for Fate Therapeutics (FATE)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

ZURAZura Bio

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Fate Therapeutics

3 Months

Daina GrayboschLeerink Partners

Success Rate

13/30 ratings generated profit

Average Return

+0.49%

Copying Daina Graybosch's trades and holding each position for 3 Months would result in 43.33% of your transactions generating a profit, with an average return of +0.49% per trade.

1 Year

Peter LawsonBarclays

Success Rate

8/21 ratings generated profit

Average Return

-1.85%

Copying Peter Lawson's trades and holding each position for 1 Year would result in 38.10% of your transactions generating a profit, with an average return of -1.85% per trade.

2 Years

Peter LawsonBarclays

Success Rate

9/21 ratings generated profit

Average Return

-2.48%

Copying Peter Lawson's trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -2.48% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

F6T Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, F6T has received 6 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. F6T average Analyst price target in the past 3 months is 4.55.

Each month's total comprises the sum of three months' worth of ratings.

F6T Financial Forecast

F6T Earnings Forecast

Currently, no earnings data available.

F6T Sales Forecast

Currently, no sales data available.

F6T Stock Forecast FAQ

What is DE:F6T’s average 12-month price target, according to analysts?

Based on analyst ratings, Fate Therapeutics Inc’s 12-month average price target is 4.55.

What is DE:F6T’s upside potential, based on the analysts’ average price target?

Fate Therapeutics Inc has 112.49% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Fate Therapeutics Inc a Buy, Sell or Hold?

Fate Therapeutics Inc has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 4 hold ratings and 0 sell ratings.

What is Fate Therapeutics Inc’s share price target?

The average share price target for Fate Therapeutics Inc is 4.55. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €6.94 ,and the lowest forecast is €1.91. The average share price target represents 112.49% Increase from the current price of €2.14.

What do analysts say about Fate Therapeutics Inc?

Fate Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Fate Therapeutics Inc?

To buy shares of DE:F6T, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Fate Therapeutics (F6T) Stock Forecast & Price Target

F6T Analyst Ratings

F6T Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Fate Therapeutics

F6T Analyst Recommendation Trends

F6T Financial Forecast

F6T Earnings Forecast

F6T Sales Forecast

F6T Stock Forecast FAQ

Detailed List of Analyst Forecasts